{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:16Z","timestamp":1791919636223,"version":"4.3.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703036"],"award-info":[{"award-number":["81703036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2018JJ3820"],"award-info":[{"award-number":["2018JJ3820"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.560615","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T06:02:38Z","timestamp":1602741758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Spectrum of Mesenchymal\u2013Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Juanni","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanliang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0950-9","article-title":"LncRNA XIST\/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.","volume":"37","author":"Liu","year":"2018","journal-title":"J Exp Clin Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1412-8","article-title":"Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.","volume":"38","author":"Liu","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more.","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1172\/JCI15418","article-title":"Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.","volume":"109","author":"Danilkovitch-Miagkova","year":"2002","journal-title":"J Clin Invest."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1073\/pnas.88.11.4892","article-title":"The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions.","volume":"88","author":"Soman","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"key":"B7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/JTO.0b013e3181ce3d1d","article-title":"High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.","volume":"5","author":"Go","year":"2010","journal-title":"J Thorac Oncol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz063.031","article-title":"A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant.","volume":"30","author":"Qu","year":"2019","journal-title":"Ann Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.onc.1209057","article-title":"Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma.","volume":"25","author":"Miller","year":"2006","journal-title":"Oncogene."},{"key":"B10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-16-1418","article-title":"A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer.","volume":"23","author":"Rosen","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/13543784.2018.1462336","article-title":"C-MET inhibitors for advanced non-small cell lung cancer.","volume":"27","author":"Pasquini","year":"2018","journal-title":"Expert Opin Investig Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1111\/cas.14180","article-title":"SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.","volume":"110","author":"Tong","year":"2019","journal-title":"Cancer Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/bio.2015.29031.hmm","article-title":"The genotype-tissue expression (GTEx) project.","volume":"13","author":"Carithers","year":"2015","journal-title":"Biopreserv Biobank."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal."},{"key":"B17","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1158\/0008-5472.CAN-17-0369","article-title":"Explore, visualize, and analyze functional cancer proteomic data using the cancer proteome atlas.","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11357-019-00080-4","article-title":"Telomere length and cancer mortality in American Indians: the strong heart study.","volume":"41","author":"Subedi","year":"2019","journal-title":"GeroScience."},{"key":"B20","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s11357-019-00108-9","article-title":"Automated lifespan determination across Caenorhabditis strains and species reveals assay-specific effects of chemical interventions.","volume":"41","author":"Banse","year":"2019","journal-title":"GeroScience."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1103-5","article-title":"HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3.","volume":"38","author":"Dong","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11357-018-0019-x","article-title":"Simultaneous assessment of cognitive function, circadian rhythm, and spontaneous activity in aging mice.","volume":"40","author":"Logan","year":"2018","journal-title":"GeroScience."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174515","article-title":"Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.","volume":"12","author":"Hou","year":"2017","journal-title":"PLoS One."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1091-5","article-title":"A novel miR-365-3p\/EHF\/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing beta5-integrin\/c-met signaling pathway.","volume":"38","author":"Huang","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1104-4","article-title":"A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.","volume":"38","author":"Luo","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1468-5","article-title":"The HOTAIR\/miR-214\/ST6GAL1 crosstalk modulates colorectal cancer procession through mediating sialylated c-Met via JAK2\/STAT3 cascade.","volume":"38","author":"Liu","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"E2987","DOI":"10.1073\/pnas.1302725110","article-title":"Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.","volume":"110","author":"Merchant","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bbrc.2004.06.132","article-title":"Insights into function of PSI domains from structure of the Met receptor PSI domain.","volume":"321","author":"Kozlov","year":"2004","journal-title":"Biochem Biophys Res Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s0968-0004(99)01416-4","article-title":"Domains in plexins: links to integrins and transcription factors.","volume":"24","author":"Bork","year":"1999","journal-title":"Trends Biochem Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0168-1656(94)90002-7","article-title":"Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering.","volume":"37","author":"Bardelli","year":"1994","journal-title":"J Biotechnol."},{"key":"B31","first-page":"49","article-title":"Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).","volume":"9","author":"Longati","year":"1994","journal-title":"Oncogene."},{"key":"B32","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1158\/1078-0432.CCR-19-0994","article-title":"Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective, multicenter, two-arms trial.","volume":"25","author":"Landi","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression.","volume":"34","author":"Awad","year":"2016","journal-title":"J Clin Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40265-020-01347-3","article-title":"Capmatinib: first approval.","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs."},{"key":"B35","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14-Mutated or MET-amplified non-small-cell lung cancer.","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40265-020-01317-9","article-title":"Tepotinib: first approval.","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs."},{"key":"B37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations.","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base.","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-019-0354-z","article-title":"Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.","volume":"39","author":"Wang","year":"2019","journal-title":"Cancer Commun."},{"key":"B40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/CAD.0000000000000765","article-title":"Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.","volume":"30","author":"Wang","year":"2019","journal-title":"Anti Cancer Drugs."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1269-x","article-title":"MET in glioma: signaling pathways and targeted therapies.","volume":"38","author":"Cheng","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-13-1610","article-title":"Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.","volume":"20","author":"Lovly","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3233\/KCA-190058","article-title":"A review of papillary renal cell carcinoma and MET inhibitors.","volume":"3","author":"Rhoades Smith","year":"2019","journal-title":"Kidney Cancer."},{"key":"B44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejca.2017.10.014","article-title":"Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.","volume":"87","author":"Schoffski","year":"2017","journal-title":"Eur J Cancer."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1158\/1078-0432.CCR-14-2685","article-title":"The MET inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient-derived xenograft models.","volume":"21","author":"Schuller","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/annonc\/mds463","article-title":"c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.","volume":"24","author":"Gibney","year":"2013","journal-title":"Ann Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.2017.72.2967","article-title":"Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer.","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30508-9","article-title":"Savolitinib for MET-driven papillary renal cell carcinoma.","volume":"18","author":"Gilbert","year":"2017","journal-title":"Lancet Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-pathol-012414-040312","article-title":"Driver and passenger mutations in cancer.","volume":"10","author":"Pon","year":"2015","journal-title":"Annu Rev Pathol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/nrc3999","article-title":"The mini-driver model of polygenic cancer evolution.","volume":"15","author":"Castro-Giner","year":"2015","journal-title":"Nat Rev Cancer."},{"key":"B51","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.cell.2020.01.032","article-title":"Passenger mutations in more than 2,500 cancer genomes: overall molecular functional impact and consequences.","volume":"180","author":"Kumar","year":"2020","journal-title":"Cell."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/jso.25275","article-title":"The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.","volume":"118","author":"Chouhan","year":"2018","journal-title":"J Surg Oncol."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0702-x","article-title":"Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations.","volume":"37","author":"Allegretti","year":"2018","journal-title":"J Exp Clin Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0719-1","article-title":"Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.","volume":"37","author":"Porru","year":"2018","journal-title":"J Exp Clin Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.prp.2018.11.010","article-title":"MET is overexpressed in microsatellite instability-high gastric carcinoma.","volume":"215","author":"Sim","year":"2019","journal-title":"Pathol Res Pract."},{"key":"B56","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10555-016-9613-5","article-title":"Genetic progression of malignant melanoma.","volume":"35","author":"Timar","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1038\/onc.2014.420","article-title":"PAX3 and ETS1 synergistically activate MET expression in melanoma cells.","volume":"34","author":"Kubic","year":"2015","journal-title":"Oncogene."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.17","article-title":"Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.","volume":"49","author":"Kim","year":"2017","journal-title":"Exp Mol Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/1535-7163.MCT-09-0824","article-title":"Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.","volume":"9","author":"Burgess","year":"2010","journal-title":"Mol Cancer Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S1470-2045(14)70023-3","article-title":"Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.","volume":"15","author":"Iveson","year":"2014","journal-title":"Lancet Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ygyno.2013.12.018","article-title":"A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a gynecologic oncology group study.","volume":"132","author":"Martin","year":"2014","journal-title":"Gynecol Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1158\/1078-0432.CCR-09-1365","article-title":"Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.","volume":"16","author":"Gordon","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-1004-z","article-title":"Systematic analysis of NLMP suggests nuclear localization of RTK\/MET kinases resemble cancer cell clearance.","volume":"38","author":"Xie","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0610-8","article-title":"MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.","volume":"11","author":"Ikeda","year":"2018","journal-title":"J Hematol Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.560615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T06:02:43Z","timestamp":1602741763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.560615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":65,"alternative-id":["10.3389\/fonc.2020.560615"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.560615","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"article-number":"560615"}}